WESTLAKE VILLAGE, Calif., June 01, 2021 (World NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical organization targeted on creating and commercializing therapies for unmet requires in immune-mediated dermatological diseases and problems, or immuno-dermatology, today declared that Rajvir (Raj) Madan has joined the enterprise as its first Chief Electronic and Information Officer. In this position, Mr. Madan will be dependable for providing the eyesight, strategic route and all round management of electronic, facts/analytics and information and facts engineering initiatives across Arcutis.
“We are thrilled to welcome Raj to our executive group. He brings deep abilities in electronic and engineering transformation in the healthcare sector, and less than his assistance, Arcutis will appear to evolve our electronic and analytics abilities to transform vital business enterprise spots as we shift towards our first likely professional start,” stated Frank Watanabe, Arcutis’ President and Chief Govt Officer. “We search forward to doing the job with Raj and are enthusiastic to leverage his experience in help of our endeavours to elevate the typical of treatment for dermatological disorders via digital and technology improvements.”
“I am fired up to sign up for Arcutis, with its daring vision to handle unmet individual requires in the healthcare dermatology sector,” explained Mr. Madan. “Arcutis’ commitment to reworking their digital and data capabilities to travel benefit throughout their numerous platforms would make this an awesome possibility, and I look ahead to contributing to the company’s ongoing growth.”
Mr. Madan provides above 20 several years of electronic transformation and innovation practical experience to the Arcutis staff. Prior to signing up for Arcutis, Mr. Madan served as the Vice President of Electronic, Facts/Analytics and Innovation for Purchaser Health care Technologies at GlaxoSmithKline (GSK), in which in partnership with the Main Digital Officer, he was dependable for driving significant features of their digital and tech transformation globally. In advance of GSK, Mr. Madan was with Novartis where by he was dependable for taking care of and providing world, regional and localized electronic methods and solutions across 3 small business units and in much more than 80 countries. In addition to health care, Mr. Madan has expertise in the buyer items sector, owning expended 14 yrs at L’Oreal in different roles, together with controlling the Electronic Tech purpose for L’Oreal Americas. Mr. Madan holds a bachelor’s diploma in laptop or computer engineering from the New Jersey Institute of Technological know-how and master’s degrees in the two company administration and facts devices from New York College Stern Faculty of Enterprise.
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a late-stage biopharmaceutical corporation focused on creating and commercializing remedies for unmet requires in immune-mediated dermatological health conditions and disorders, or immuno-dermatology. The firm is leveraging latest improvements in immunology and irritation to acquire differentiated therapies against biologically validated targets to solve persistent treatment troubles in really serious illnesses of the pores and skin. Arcutis’ robust pipeline includes four novel drug candidates at this time in growth for a array of inflammatory dermatological situations. The company’s direct solution candidate, topical roflumilast, has the potential to revitalize the regular of treatment for plaque psoriasis, atopic dermatitis, scalp psoriasis, and seborrheic dermatitis. For far more details, visit www.arcutis.com or observe the company on LinkedIn and Twitter.
This push release includes “ahead-on the lookout” statements, including, between many others, statements about the potential for roflumilast to revolutionize the common of care in plaque psoriasis and other inflammatory dermatological disorders. These statements entail considerable recognised and unknown dangers, uncertainties and other elements that may perhaps cause our actual results, amounts of exercise, overall performance, or achievements to be materially distinctive from the info expressed or implied by these ahead-searching statements and you ought to not location undue reliance on our ahead-on the lookout statements. Dangers and uncertainties that may possibly trigger our precise effects to vary involve threats inherent in the clinical enhancement course of action and regulatory acceptance method, the timing of regulatory filings, and our ability to protect our mental home. For a further more description of the hazards and uncertainties applicable to our enterprise, see the “Danger Factors” area of our Kind 10-K filed with U.S. Securities and Trade Fee (SEC) on February 16, 2021, as perfectly as any subsequent filings with the SEC. We undertake no obligation to revise or update information herein to replicate activities or circumstances in the long term, even if new facts results in being offered.
Investor and Media Get in touch with: